Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Regenerative Medicine International (HKSE:08158) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
China Regenerative Medicine International Pretax Margin % Related Terms
China Regenerative Medicine International Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International Pretax Margin % Chart
China Regenerative Medicine International Annual Data
HKSE:08158 vs VRTX, REGN, RVMD: Pretax Margin % Comparison
For the Biotechnology subindustry, China Regenerative Medicine International's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Regenerative Medicine International Pretax Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Regenerative Medicine International (HKSE:08158) has a Pretax Margin % of 23.69% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on China Regenerative Medicine International and its competitors. According to the industry distribution chart, China Regenerative Medicine International ranks #124 out of 944 companies in the Biotechnology industry, placing it in the top 13.1%.
Is China Regenerative Medicine International's Pretax Margin % too high?
China Regenerative Medicine International's current Pretax Margin % is 23.69%. Based on the distribution chart, China Regenerative Medicine International ranks #124 out of 944 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, China Regenerative Medicine International has a GF Score™ of 30/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does China Regenerative Medicine International's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, China Regenerative Medicine International ranks #124 out of 944 companies for Pretax Margin %. This places China Regenerative Medicine International in the top 13% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on China Regenerative Medicine International and its competitors. China Regenerative Medicine International's current Pretax Margin % is 23.69%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Regenerative Medicine International stock overvalued right now?
Based on GuruFocus' analysis, China Regenerative Medicine International (HKSE:08158) is currently considered Possible Value Trap. The stock's GF Value™ is HK$0.63, compared to a current price of HK$0.23 — trading 63.2% below its estimated fair value. The current Pretax Margin % is 23.69%. China Regenerative Medicine International's overall GF Score™ is 30/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For China Regenerative Medicine International (HKSE:08158), the current Pretax Margin % is 23.69% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Regenerative Medicine International (HKSE:08158) Overvalued in 2026?
Based on GuruFocus' analysis, China Regenerative Medicine International stock appears to be undervalued.
The current stock price of HK$0.23 is trading 63.2% below its estimated GF Value™ of HK$0.63.
GuruFocus considers China Regenerative Medicine International to be Possible Value Trap.
Key valuation signals for HKSE:08158:
Pretax Margin %: 23.69%
GF Value™: HK$0.63 vs. price of HK$0.23 (63.2% below fair value)
No single metric tells the full story. See the HKSE:08158 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Regenerative Medicine International Ltd is an investment holding company. The company is engaged in the provision of healthcare products and services. It is engaged in research and development, production and sales of tissue engineering and regenerative medicine products. The business scope of company includes tissue engineering, cosmetics, cell storage, preparation and therapy, hospitals administration and other business division. The segments of the company are Aesthetic medical and beauty services and Medical services. The majority of the company's revenue is derived from its Aesthetic medical and beauty services segment that provides medical beauty products and services. Geographically, the Hong Kong accounts for the majority of the revenue and also has a presence in PRC.
30GF Score
Get the complete analysis for HKSE:08158
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:08158 has been successfully added to your 
